Adalimumab vs active comparators
Adverse events · People with quiescent Crohn's disease (ileocolic resection)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
185 questions · 187 findings · 30 reviews
No studies found 32 · 17.1%GRADE not reported 4 · 2.1%Very low 58 · 31%Low 59 · 31.6%Moderate 29 · 15.5%High 5 · 2.7%
Adalimumab vs placebo
Adverse events · Participants with Crohn's disease in remission
Adalimumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
- RR 1.01 [0.94, 1.09]4 studies · 1012 participantsHigh
5‐ASA vs placebo
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASAs showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.07 [0.6, 1.91]4 studies · 466 participantsLow
High dose 5‐ASA vs low dose 5‐ASA
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.04 [0.15, 7.24]1 study · 206 participantsLow
5‐ASA vs purine antimetabolites
Adverse events · people with surgically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with purine antimetabolites (low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.11 [0.97, 1.27]5 studies · 425 participantsLow
5‐ASA vs anti TNF‐ɑ
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes adverse events compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.13 [0.75, 1.71]1 study · 34 participantsVery low
Sulphasalazine vs placebo
Adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
5‐ASA vs no treatment
Adverse events · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes adverse events compared with no treatment (very low certainty).
1 finding from 1 review
- Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 5 [0.25, 101.81]110 participantsVery low
Azathioprine or 6‐mercaptopurine vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with 5‐aminosalicylic acid (low certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.89 [0.74, 1.07]4 studies · 346 participantsLow
Azathioprine or 6‐mercaptopurine vs anti TNF‐ɑ
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with anti TNF‐α (low certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.13 [0.83, 1.53]2 studies · 117 participantsLow
Azathioprine or 6‐mercaptopurine vs placebo
Adverse events · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- Azathioprine and 6‐mercaptopurine for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.36 [0.57, 3.27]2 studies · 168 participantsLow
Briakinumab vs placebo
Adverse events · people with moderate to severe Crohn's disease in remission
Briakinumab showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 1.02 [0.67, 1.55]1 study · 104 participantsLow
Ustekinumab vs placebo
Adverse events · people with moderate to severe Crohn's disease in remission
Ustekinumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
- Anti‐IL‐12/23p40 antibodies for maintenance of remission in Crohn's disease 2019 · Cochrane Headline outcomes onlyRR 0.94 [0.87, 1.03]2 studies · 541 participantsHigh
Intervention not reported
Adverse events · Patients with active Crohn's disease
The intervention showed no clear difference in adverse events (moderate certainty).
1 finding from 1 review
- RR 0.9 [0.74, 1.09]3 studies · 531 participantsModerate
Elemental vs non‐elemental enteral feeds
Adverse events · induction of remission in Crohn's disease
It is very uncertain whether elemental changes adverse events compared with non‐elemental enteral feeds (very low certainty).
1 finding from 1 review
- Enteral nutritional therapy for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 1.01 [0.62, 1.65]9 studies · 323 participantsVery low
Enteral nutrition vs corticosteroids
Adverse events · induction of remission in Crohn's disease
It is very uncertain whether enteral nutrition changes adverse events compared with corticosteroids (very low certainty).
1 finding from 1 review
- Enteral nutritional therapy for induction of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 1.39 [0.62, 3.11]7 studies · 389 participantsVery low
Elemental formula supplements vs no supplementation
Adverse events · Participants with Crohn's disease in remission
1 finding from 1 review
- Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyno estimate extracted1 study · 51 participantsGRADE not reported
Enteral nutrition vs 6‐MP
Adverse events · Participants with Crohn's disease in remission
Enteral nutrition showed no clear difference in adverse events compared with 6‐MP (low certainty).
1 finding from 1 review
- Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyRR 0.23 [0.03, 1.98]1 study · 62 participantsLow
Enteral nutrition vs mesalamine
Adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
- Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Elemental formula supplements vs polymeric formula supplements
Adverse events · Participants with Crohn's disease in remission
The review found no eligible studies for this question.
1 finding from 1 review
- Enteral nutrition for maintenance of remission in Crohn's disease 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found